Science · Open for opinions
Will research using organoids in a space environment result in a clinical protocol (phase 1 or higher) for a rare pediatric disease registered by March 2027?
An article published in November 2026 in Precision Clinical Medicine proposes the use of the space environment as a stress platform… 89 opinions, 92% No
- Yes — 8%
- No — 92%
Deadline: March 31, 2027 at 12:00 AM UTC · 89 opinions
Resolution rules
An article published in November 2026 in Precision Clinical Medicine proposes the use of the space environment as a stress platform for iPSC models and organoids, identifying shared molecular signatures between spaceflight stress and rare pediatric diseases, with potential for acceptance
Source: www.news-medical.net
Frequently asked questions about this event
How is this event resolved?
Resolve 'Sim' se ensaio clínico de fase 1 ou superior derivado de pesquisa com células-tronco pluripotentes induzidas (iPSC) ou organoides desenvolvidos em ambiente de microgravidade espacial para tratamento de doença pediátrica rara for registrado no ClinicalTrials.gov ou base equivalente da ANVISA/EMA até 31 de março de 2027. Fonte: ClinicalTrials.gov ou base de registros equivalente.
How are points scored?
Points depend on the share of votes your side had when you gave your opinion. Being right earns 100 minus that share. Being wrong costs that share.
Right now No has 92% of the votes: an opinion on it that turns out right earns about 8 points, a wrong one costs about 92.